$SAGE • The FDA's approval of Intra-Cellular Therapies' (ITCI +191.6%) schizophrenia drug bodes well for other companies with therapies for the central nervous system, writes Stifel analyst Paul Matteis. • He points to Sage Therapeutics (SAGE -1.1%), Acadia Pharmaceuticals (ACAD -1.7%), Karuna Therapeutics (KRTX -7.3%), and, to some extent, Biogen (BIIB +0.6%). • The recent approval shows that regulators will "often look at a mixed efficacy package in CNS through a 'glass half full lens'," given that ITCI's drug failed in one of the two Phase 3 studies, he writes.